ArticleScientific reports2019
Exploiting chitosan and gold nanoparticles for antimycobacterial activity of in silico identified antimicrobial motif of human neutrophil peptide-1.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 63 citations in OpenAlex.
- Comparative Biological and Functional Profiling of Single-Position Cysteine Substitutions in the HNP-1-Derived Peptide Pep-H AgainstAntibiotics (Basel, Switzerland) · 2026Article
- Review
- Redefining Therapies for Drug-Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design.Advanced healthcare materials · 2026Review
- Article
- New Frontiers in Fighting Mycobacterial Infections: Venom-Derived Peptides.Probiotics and antimicrobial proteins · 2025Review
- Antimicrobial Peptide Delivery Systems as Promising Tools Against Resistant Bacterial Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Using gold-based nanomaterials for fighting pathogenic bacteria: from detection to therapy.Mikrochimica acta · 2024Review
- Recent advances in targeted antibacterial therapy basing on nanomaterials.Exploration (Beijing, China) · 2023Review
- Antimicrobial Peptides against Bacterial Pathogens: Innovative Delivery Nanosystems for Pharmaceutical Applications.Antibiotics (Basel, Switzerland) · 2023Review
- Antimicrobial peptides as drugs with double response againstFrontiers in microbiology · 2023Review
- Current Advances in Lipid and Polymeric Antimicrobial Peptide Delivery Systems and Coatings for the Prevention and Treatment of Bacterial Infections.Pharmaceutics · 2021Review
- Effect of Lipopeptide-Loaded Chitosan Nanoparticles on Candida albicans Adhesion and on the Growth of Leishmania major.Applied biochemistry and biotechnology · 2021Article
- Application of "Magnetic Anchors" to Align Collagen Fibres for Axonal Guidance.Gels (Basel, Switzerland) · 2021Article
- Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Mycogenic Metal Nanoparticles for the Treatment of Mycobacterioses.Antibiotics (Basel, Switzerland) · 2020Review
- Smart Gold Nanostructures for Light Mediated Cancer Theranostics: Combining Optical Diagnostics with Photothermal Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- A competent bidrug loaded water soluble chitosan derivative for the effective inhibition of breast cancer.Scientific reports · 2020Article
- Advances in Lipid and Metal Nanoparticles for Antimicrobial Peptide Delivery.Pharmaceutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The upsurge of drug resistant tuberculosis is major health threat globally. To counteract, antimicrobial peptides are being explored as possible alternatives. However, certain limitations of peptide-based drugs such as potential toxicity, high cost and relatively low stability need to be addressed to enhance their clinical applicability. Use of computer predicted short active motifs of AMPs along with nanotechnology could not only overcome the limitations of AMPs but also potentiate their antimicrobial activity. Therefore, present study was proposed to in silico identify short antimicrobial motif (Pep-H) of human neutrophil peptide-1 (HNP-1) and explore its antimycobacterial activity in free form and using nanoparticles-based delivery systems. Based on colony forming unit analysis, motif Pep-H led to killing of more than 90% M. tb in vitro at 10 μg/ml, whereas, similar activity against intracellularly growing M. tb was observed at 5 μg/ml only. Thereafter, chitosan (244 nm) and gold nanoparticles (20 nm) were prepared for Pep-H with both the formulations showing minimal effects on the viability of human monocyte derived macrophages (MDMs) and RBC integrity. The antimycobacterial activity of Pep-H against intracellular mycobacteria was enhanced in both the nanoformulations as evident by significant reduction in CFU (>90%) at 5-10 times lower concentrations than that observed for free Pep-H. Thus, Pep-H is an effective antimycobacterial motif of HNP-1 and its activity is further enhanced by chitosan and gold nanoformulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.